Among T2DM women, we did not find any significant difference in resistin levels according to the use of secretagogues drugs (9.85 ± 3.49 vs 10.79 ± 4.75 ng/ml in secretagogues users and non users, respectively; P = 0.191); similarly no differences were noted according to the use of other hypoglycaemic drugs including metformin and/or insulin (data not shown). The gene discussed is RETN; the disease is type 2 diabetes mellitus.